Gurugram headquartered Eli Lilly and Company (India) has announced its strategic partnership in India to enhance the reach of Lilly’s Diabetes products – Humalog [Insulin Lispro IP (rDNA Origin) injection] and Trulicity (Dulaglutide).

As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly diabetes products – Humalog and Trulicity to Cipla, subject to all regulatory approvals. 

Lilly will continue to maintain its existing operating model for the remaining portfolio of products. Cipla will leverage its capabilities and robust distribution strengths to engage healthcare professionals and expand access to these treatments for patients who need them. 

Commenting on the partnership, Luca Visini, MD, India Subcontinent, Lilly India, said, “Developing strategic partnerships to adopt different operating models is key to enabling Lilly’s global efforts to make innovative medicines available to more people in India and around the world.”